Signalexis

Signalexis is a private clinical-stage biopharmaceutical company headquartered in American Fork, Utah, founded in 2023. The company is dedicated to developing novel small molecule therapeutics and molecular glue degraders that target critical signaling pathways involved in tumor growth, metastasis, and immune evasion. Signalexis leverages its proprietary AI-driven drug discovery platform, MolecuLern, in partnership with Biolexis Therapeutics, to rapidly identify and optimize high-quality drug candidates. Its lead program, SLX-0528, is an oral RORγT inverse agonist that has completed Phase 1 and is advancing into Phase 2 clinical trials for pancreatic cancer. The company's diverse pipeline also includes programs targeting CDK9, TGM2, GCN2, and FLT3/MELK for various oncology and immune-mediated indications.